Skip to content
Clinical Trials – home
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Sponsor

IRCCS Istituto Nazionale Tumori Fondazione Pascale

Italy Via Mariano Semmola 52, 80131 Naples, Italy

About the sponsor

Research activity includes colorectal cancer, rectal cancer, pancreatic cancer, cholangiocarcinoma, hepatocellular carcinoma, and gastrooesophageal carcinoma. The portfolio also covers metastatic colorectal cancer, locally advanced pancreatic cancer, and metastatic pancreatic ductal adenocarcinoma.

  • RAS-mutant metastatic colorectal cancer
  • RAS/BRAF wild-type metastatic colorectal cancer
  • Locally advanced rectal cancer
  • Locally advanced cholangiocarcinoma

Interest also extends to organ-sparing treatment and neoadjuvant approaches in selected digestive tract malignancies.

About Specializations

IRCCS Istituto Nazionale Tumori Fondazione Pascale runs clinical trials in conditions such as Colorectal cancer metastatic, Rectal cancer, Ovarian cancer recurrent, Endometrial cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

25 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Relugolix
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.